| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Ontuxizumab Basic information |
| Product Name: | Ontuxizumab | | Synonyms: | Ontuxizumab;Research Grade Ontuxizumab (DHJ61001);MORAb-004;Research Grade Ontuxizumab | | CAS: | 946415-62-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ontuxizumab Structure]() |
| | Ontuxizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ontuxizumab Usage And Synthesis |
| Uses | Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1]. | | in vivo | Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice[1]. | Animal Model: | Human CD248 knock-in mice[1] | | Dosage: | 50 mg/kg | | Administration: | Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days | | Result: | Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
|
| | References | [1] Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40. DOI:10.18632/oncotarget.4559 |
| | Ontuxizumab Preparation Products And Raw materials |
|